sq-23377 and titanium-dioxide

Adoptive cell therapies are showing very promising results in the fight against cancer. However, these therapies are expensive and technically challenging in part due to the need of a large number of specific T cells, which must be activated and expanded in vitro. Here we describe a method to activate primary human T cells using a combination of nanostructured surfaces functionalized with the stimulating anti-CD3 antibody and the peptidic sequence arginine-glycine-aspartic acid, as well as costimulatory agents (anti-CD28 antibody and a cocktail of phorbol 12-myristate 13-acetate, ionomycin, and protein transport inhibitors). Thus, we propose a method that combines nanotechnology with cell biology procedures to efficiently produce T cells in the laboratory, challenging the current state-of-the-art expansion methodologies.

Topics: Antibodies, Immobilized; CD28 Antigens; CD3 Complex; Cell Adhesion; Cells, Cultured; Coated Materials, Biocompatible; Gold; Humans; Immunotherapy, Adoptive; Ionomycin; Lymphocyte Activation; Nanostructures; Oligopeptides; Surface Properties; T-Lymphocytes; Tetradecanoylphorbol Acetate; Titanium